γ-linolenic acid (Borage Oil) / IL6 Cancer Research Results

GLA, γ-linolenic acid (Borage Oil): Click to Expand ⟱
Features:

γ-Linolenic acid (GLA) — an omega-6 polyunsaturated fatty acid (18:3 n-6) found in high concentration in borage oil, evening primrose oil, and blackcurrant seed oil. Metabolized to dihomo-γ-linolenic acid (DGLA) → precursor of anti-inflammatory eicosanoids (e.g., PGE1).

Primary mechanisms (conceptual rank):
1) Membrane lipid remodeling → altered eicosanoid balance (↑ PGE1; DGLA-derived metabolites)
2) Modulation of inflammatory signaling (↓ NF-κB tone; context-dependent)
3) Lipid peroxidation susceptibility (PUFA-driven ROS shifts)
4) Potential anti-proliferative effects (high concentration only; tumor models)
5) Metabolic signaling interaction (PPAR activation context-dependent)

Bioavailability / PK relevance: Orally absorbed and incorporated into membrane phospholipids; rapidly elongated to DGLA. Plasma levels achievable with supplementation; cellular effects reflect incorporation over days–weeks (remodeling).

In-vitro vs oral exposure: Direct tumor cytotoxicity generally observed at supra-physiologic concentrations; physiologic doses mainly alter lipid signaling rather than induce apoptosis.

Clinical evidence status: Used for inflammatory conditions (e.g., dermatitis, RA); oncology data limited and inconsistent; no cancer approval.

GLA (abundant in borage oil) has shown anti-proliferative and pro-apoptotic effects on multiple cancer cell lines and in animal models (mechanisms include ER stress, mitochondrial dysfunction, altered eicosanoid signaling).
-Borage plants can contain unsaturated PAs(Pyrrolizidine alkaloids) which are hepatotoxic and genotoxic/carcinogenic. Many authorities advise only using borage oil products certified PA-free, and caution against long-term or high-dose use.
-γ-gamma linolenic acid (GLA, 18:3n-6) are polyunsaturated fatty acids (PUFA) that improve the human health

γ-Linolenic Acid (Borage Oil) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane lipid remodeling (DGLA incorporation) ↑ substrate (context-dependent) ↑ membrane incorporation G Phospholipid composition shift Changes membrane fluidity and eicosanoid substrate pool; time-dependent remodeling.
2 Eicosanoid balance (PGE1 vs AA-derived eicosanoids) ↔ / ↓ pro-inflammatory tone ↓ inflammation G Anti-inflammatory modulation DGLA-derived PGE1 often anti-inflammatory; may counterbalance arachidonic acid metabolites.
3 ROS / Lipid peroxidation ↑ (PUFA-dependent; dose-dependent) ↔ / ↑ (high dose) P/R Lipid oxidative susceptibility Highly unsaturated structure increases peroxidation potential; may sensitize tumors to oxidative stress.
4 NF-κB ↓ (context-dependent) ↓ R/G Reduced inflammatory transcription Often secondary to altered eicosanoid signaling.
5 PPAR (α/γ) ↑ (model-dependent) ↑ R/G Lipid metabolic regulation GLA and derivatives may activate PPAR pathways influencing lipid and glucose metabolism.
6 Apoptosis ↑ (high concentration only) ↔ R/G Mitochondrial apoptosis (experimental) Reported in certain tumor lines at supra-physiologic levels.
7 Ferroptosis ↑ (theoretical; PUFA-linked) ↔ R/G Lipid peroxidation vulnerability PUFA enrichment can enhance ferroptotic susceptibility depending on antioxidant context.
8 HIF-1α ↔ (limited evidence) ↔ G Not primary axis No consistent direct modulation reported.
9 NRF2 ↔ / ↑ (adaptive; context-dependent) ↔ R/G Redox-response adjustment May activate antioxidant response secondary to lipid peroxidation stress.
10 Ca²⁺ signaling ↔ (membrane-dependent) ↔ P/R Membrane microdomain modulation Changes in lipid composition can subtly influence ion channel behavior.
11 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Context-dependent effects Physiologic doses primarily anti-inflammatory; anti-cancer cytotoxicity not clinically established.

TSF legend:
P: 0–30 min (lipid oxidation events)
R: 30 min–3 hr (acute signaling shifts)
G: >3 hr (membrane remodeling and phenotype changes)
IL6, Interleukin-6: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Interleukin-6 (IL-6) is a cytokine that plays a significant role in inflammation and the immune response. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts.
IL-6 can promote tumor cell proliferation and survival. Many cancer cells produce IL-6, which can create an autocrine loop that supports their growth.
IL-6 is a high-value inflammatory biomarker in cancer, reporting cytokine burden, catabolic stress, and STAT3-linked survival signaling. While not tumor-specific, elevated and rising IL-6 strongly predicts poor prognosis and limited treatment tolerance, making it an important system-state indicator alongside CRP and ferritin.


Scientific Papers found: Click to Expand⟱
4511- GLA,    Gamma-Linolenic Acid (GLA) Protects against Ionizing Radiation-Induced Damage: An In Vitro and In Vivo Study
- vitro+vivo, Nor, RAW264.7
*radioP↑, *ROS↓, *DNAdam↓, *IL6↓, *TNF-α↓, *IL10↓, *NF-kB↓, *SOD↑, *Catalase↑, *GSH↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

Catalase↑, 1,   GSH↑, 1,   ROS↓, 1,   SOD↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↓, 1,   IL6↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

radioP↑, 1,  
Total Targets: 11

Scientific Paper Hit Count for: IL6, Interleukin-6
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:374  Target#:158  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page